Phosphoinositide 3-kinase α inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 7, 2013, Pages 789-799

  Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cancer; Kinase selectivity; MTOR; Patent review; PI3K inhibitor; PI3K inhibitor

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; APITOLISIB; BUPARLISIB; COPANLISIB; DNA DEPENDENT PROTEIN KINASE; GNE 317; GNE 477; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PF 04691502; PF 05212384; PHENMETRAZINE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PKI 587; PROTEIN KINASE B; PWT 33597; UNCLASSIFIED DRUG; VS 5584;

BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN HCT116; CELL STRAIN MCF 7; DRUG INDUSTRY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; IC 50; PATENT; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; SIGNAL TRANSDUCTION;

EID: 84879333273     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.779673     Document Type: Review

References (58)

1. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Ann Rev Biochem 1998;67:481-507 (Pubitemid 28411136)
2. Downward J. PI 3-kinase, Akt and cell survival. Sem Cell Dev Biol 2004;15:177-82 (Pubitemid 38251646)
3. Parsons R, Simpson L. PTEN and cancer. Methods Mol Biol 2003;222:147-66
4. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006;18:77-82 (Pubitemid 43740454)
5. Lannutti BJ, Meadows SA, Herman SEM, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591-4
6. Fruman DA, Rommel C. PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov 2011;1:562-72
7. Norman P. Selective PI3Kdelta inhibitors, a review of the patent literature. Expert Opin Ther Pat 2011;21:1773-90
8. Jamieson S, Flanagan J, Kolekar S, et al. Characterisation of a selective inhibitor of the p110alpha isoform of PI 3-kinase and use to demonstrate that p110alpha activity is necessary for signalling specifically in cells harbouring H1074R mutations in PIK3CA. Biochem J 2011;428:53-62
9. Amgen, Inc. Inhibitors of PI3 kinase. WO2010108074; 2010
10. Boehringer Ingelheim. New 5-alkynyl-pyridines. WO2012101184; 2012
11. Boehringer Ingelheim. New 5-alkynyl-pyridines. WO20121101186; 2012
12. CNIO. Fused imidazo[2,3d]pyrazines as PI3 kinase inhibitors. WO2011036461; 2011
13. CNIO. Tricyclic compounds for use as kinase inhibitors. WO2012020227; 2012
14. Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3K alpha. WO2012065019; 2012
15. Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use. WO2012065057; 2012
16. Exelixis, Inc. Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture. WO2012071519; 2012
17. Exelixis, Inc. Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture. WO2012074069; 2012
18. Exelixis, Inc. MetHod of treating lymphoma using pyridopyrimidinone inhibitors of PI3K/MTOR. WO2012149308; 2012
19. Glaxo Group Ltd. Novel compounds. WO2011067364; 2011
20. Glaxo Group Ltd. Benzopyrazole derivatives as inhibitors of PI3 kinase. WO2011067365; 2011
21. Glaxo Group Ltd. Indazole derivatives as PI3 kinase inhibitors. WO2011067366; 2011
22. Intellikine. Heterocyclic compounds and uses thereof. WO2011022439; 2011
23. Intellikine. Heterocyclic compounds and uses thereof. WO2011149937; 2011
24. Eli Lilly and Co. Imidazo[4,5-c]quinolin-2-one compound and its use as PI3 kinase/mTOR dual inhibitor. WO2012097039; 2012
25. Novartis. Organic compounds. WO2010029082; 2010
26. Novartis. Organic compounds. WO2009080705; 2009
27. Sun M, Hillmann P, Hofmann B, et al. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci USA 2010;107:15547-52
28. Novartis. Novel heterocyclic derivatives. WO2012104776; 2012
29. Yaguchi S, Fukui Y, Koshimizu I, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006;98:545-56 (Pubitemid 43898818)
30. Pathway Therapeutics Ltd. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy. WO2011005119; 2011
31. Pathway Therapeutics Ltd. 1,3,5-Triazinyl benzimidazoles and their use in cancer therapy. WO2012044641; 2012
32. Wyeth LLC. (2-Aryl-7H-pyrrolo[2,3d] pyrimidin-4-yl)morpholine compounds, their use as mTOR and PI3 kinase inhibitors, and their synthesis. WO2010002954; 2010
33. Wyeth LLC. Ring fused ureidoaryl-and carbamoylaryl-bridged morpholinopyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesis. WO2010120987; 2010
34. Wyeth LLC. 5,6,7,8-Tetrahydropyrido [4,3-d]pyrimidine compounds, their use as mTOR, PI3 and HSMG-1 kinase inhibitors, and their synthesis. WO2010120991; 2010
35. Wyeth LLC. Ureidoaryl-and carbamoylaryl-morpholino-pyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesis. WO2010120994; 2010
36. Wyeth LLC. 5,6,7,8-Tetrahydropyrido [3,4-d]pyrimidine compounds, their use as mTOR, PI3 and HSMG-1 kinase inhibitors, and their synthesis. WO2010120996; 2010
37. Wyeth LLC. Pyrimidine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesis. WO2010120998; 2010
38. Avila Therapeutics, Inc. PI3 kinase inhibitors and uses thereof. WO2012122383; 2012
39. Intellikine. Reactive mTOR and PI3 kinase inhibitors and uses thereof. WO2012154608; 2012
40. Intellikine. Reactive PI3 kinase inhibitors and uses thereof. WO2012154610; 2012
41. Clarke PA, Workman P. Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials. J Clin Oncol 2012;30:331-3
42. Schenone S, Brullo C, Musumeci F, et al. ATP-competitive inhibitors of mTOR: an update. Curr Med Chem 2011;18:2995-3014
43. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30:282-90
44. Sabbah DA, Brattain MG, Zhong H. Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go? Curr Med Chem 2011;18:5528-44
45. Vijapurkar U, Robillard L, Zhou S, et al. mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations. Cancer Lett 2012;326:168-75
46. Shimizu T, Tolcher AW, Papadopoulos KP, et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012;18:2316-25
47. Hoeflich KP, Merchant M, Orr C, et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 2012;72:210-19
48. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:121-30
49. Folkes AJ, Ahmadi K, Alderton WK, et al. The identification of 2-(1Hindazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4- ylthieno[ 3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008;51:5522-32
50. Heffron T, Berry G, Castanedo G, et al. Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor. Bioorg Med Chem Lett 2010;20:2408-11
51. Sutherlin DP, Bao L, Berry M, et al. Discovery of a potent, selective, and orally available Class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem 2011;54:7579-87
52. Heffron TP, Salphati L, Alicke B, et al. The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase alpha. J Med Chem 2012;55:8007-20
53. Williams M, Hart S, Bonday Z, et al. A novel series of tetrasubstituted purines potently inhibit mTOR and PI3K, exhibit striking selectivity and demonstrate good pathway inhibition in vivo. Poster at American Association of Cancer Research Special Conference: Targeting PI3K/mTOR Signaling in Cancer; 24-27 February 2011; San Francisco
54. Matthews DJ, O'Farrell M, James J, et al. Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2-6 April 2011; Orlando, FL, Cancer Res 2011;71S:Abstract 4485
55. Venkatesan AM, Dehnhardt CM, Delos Santos E, et al. Bis(morpholino-1,3,5- triazine) derivatives: potent adenosine 5-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: Discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem 2010;53:2636-45
56. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63
57. Scott WJ, Hentemann M, Rowley B, et al. Novel 2,3-dihydroimidazo[1,2-c] quinazoline PI3K inhibitors: discovery and structure-activity relationship [abstract 444/poster 185]. 22nd EORTC-NCI-AACR Symposium; Berlin; 2010
58. Cheng H-M, Bagrodia S, Bailey S, et al. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. Med Chem Commun 2010;1:139-44